2017-11-24T12:07:30
US FDA approves first two-drug regimen for certain patients with HIV The US Food and Drug Administration has approved Juluca the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 HIV 1 instead of three or more drugs included in standard HIV treatment. Juluca is a fixed dose tablet containing two previously approved drugs dolutegravir and rilpivirine to treat adults with HIV 1 infections whose virus is currently suppressed on a stable regimen for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.